You cannot add another "Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer" to your cart. View cart

Article: P12 SENSITIVITY OF THE NEW STAGO PT STA-NEOPTIMAL REAGENT FOR FACTOR DEFICIENCY ON STAGO STA-R EVOLUTION

€2.42

SKU: product-article-23773 Category: General

Description
Reviews (0)

Description

P12 SENSITIVITY OF THE NEW STAGO PT STA-NEOPTIMAL REAGENT FOR FACTOR DEFICIENCY ON STAGO STA-R EVOLUTION

Reviews

There are no reviews yet.

Be the first to review “Article: P12 SENSITIVITY OF THE NEW STAGO PT STA-NEOPTIMAL REAGENT FOR FACTOR DEFICIENCY ON STAGO STA-R EVOLUTION”

Top

Article: P12 SENSITIVITY OF THE NEW STAGO PT STA-NEOPTIMAL REAGENT FOR FACTOR DEFICIENCY ON STAGO STA-R EVOLUTION

Description

Reviews

Related products

Article: Highlights in digestive oncology

Article: Highlights in urologic cancer

Article: Highlights in squamous cell carcinoma of the head and neck

Article: Highlights in respiratory oncology